• Fri, April 25, 2025

by: ThePrint

Suven Pharmaceuticals to acquire controlling stake in US-based company NJ Bio

New Delhi [India], December 7 (ANI): Listed pharma company, Suven Pharmaceuticals has announced the acquisition of a controlling stake in US-based NJ Bio Inc. The company informed stock exchanges that the controlling stake came with an investment of USD 64.4 million. Show Full Article The transaction is expected to close before the end of December […]

by: KUTV

Alphabet boosts dividend and plans new share buyback, reassuring investors amid antitrust, AI worries

Alphabet earnings top estimates amid a myriad of investor worries.

by: CNBC

We're putting a big weekly winner in the Bullpen but see more room for the stock to run

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

by: WOPRAI

Short squeeze is starting in shares of NXT at $43.505, after crossing above the $43.349 Trigger Price

by: Fortune

Markets notch small gains as tech stocks jump and Trump delivers mixed signals on tariffs

President Donald Trump said he's made "200 deals" on tariffs but declined to say with whom.

by: MarketWatch

14 financial pros reveal the No. 1 money concern their clients are facing now

Investing long term and building a 'resilience reserve' are just a few ways advisers are guiding their clients through an unstable market

by: BBC

MLC to expand with investment from New Zealand Cricket

A new Major League Cricket franchise team will launch in 2027 with direct investment from New Zealand Cricket (NZC). Terms have been agreed between NZC and a US-based consortium True North Sports Ventures (TNS) in what will be an unprecedented overseas franchise investment for a national governing body. A statement from NZC said they will provide "high-performance and operational support" to the MLC franchise "including coaching, management, and support staff, as well as integrating the franchise into NZC's domestic high-performance ecosystem".

by: Forbes

Investing In The Age Of AI: Lessons From The Dot-Com Era

People who barely knew what a website was were suddenly investing in any company with "dot-com" in its name. Tech stocks soared—and soon enough, the bubble burst. Today, the rise of AI is giving me a feeling of deja vu all over again.

by: Kiplinger

My Great Retirement Dream: Sell My House, Downsize, Live off the Proceeds and Dabble in Stocks. Can I Do It?

For me, retirement is at least fifteen years away, but that doesn't mean I can't fantasize about the future. My great retirement dream? Sell my house once my two kids are off to college, downsize, and use some of the proceeds to dabble in the stock market.

by: MoneyWeek

Which investments can I hold in a stocks and shares ISA - and which ones are banned?

HMRC has a list stating which investments are allowed in ISAs, but sometimes investors, and even ISA providers, get confused by the rules. Here's what you need to know when picking your investments.

by: Investopedia

Markets News, April 25, 2025: Stocks Rise to Extend Winning Streak to Four Days as Tesla, Nvidia Lead Tech Rally; Major Indexes Post Gains for Week

Stocks closed higher Friday for the fourth straight day, led by big tech sector gains, as investors set aside ongoing uncertainty about tariffs and the economic outlook.

by: CNBC

What Alphabet's earnings mean for Meta Platforms and our AI chip stocks

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.

by: WOPRAI

Short squeeze is starting in shares of DSHKP at $7.5, after crossing above the $7.288 Trigger Price

by: Fortune

Private markets are booming. Here's what investors need to know

Deloitte predicts private market investments among retail investors will grow "exponentially" in the next five years.

by: Forbes

Move Over Fab 4 Stocks, Buy These 3 Instead

Looking for alternatives to the Fab 4 stocks, but not sure where to look? See which stocks may be the best picks to consider.

by: WOPRAI

Short squeeze is starting in shares of CX at $5.855, after crossing above the $5.844 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of MRVL at $58.75, after crossing above the $58.74 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of ADYYF at $1671, after crossing above the $1657.655 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of UBND at $21.65, after crossing above the $21.625 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of FSUN at $35.83, after crossing above the $35.797 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of EVLV at $3.91, after crossing above the $3.863 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of ESMC at $0.22, after crossing above the $0.175 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of ADUS at $100.34, after crossing above the $100.326 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of PRCH at $5.66, after crossing above the $5.653 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of QNCX at $1.22, after crossing above the $1.218 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of IZEA at $1.86, after crossing above the $1.832 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of IFNNY at $34.38, after crossing above the $34.224 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of ENS at $86.82, after crossing above the $86.555 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of CDRE at $30.67, after crossing above the $30.578 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of BSM at $14.43, after crossing above the $14.418 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of BCTF at $11.45, after crossing above the $11.363 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of BCRX at $8.43, after crossing above the $8.428 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of CPS at $14.025, after crossing above the $14.017 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of RGBPP at $0.079, after crossing above the $0.073 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of CBSTF at $0.047, after crossing above the $0.045 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of YOU at $25.895, after crossing above the $25.757 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of POCI at $4.37, after crossing above the $4.345 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of OMEX at $1.535, after crossing above the $1.209 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of MNTS at $1.96, after crossing above the $1.921 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of LZM at $3.834, after crossing above the $3.833 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of HDRSF at $0.074, after crossing above the $0.073 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of EUO at $29.51, after crossing above the $29.409 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of ECCX at $24.88, after crossing above the $24.529 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of CORZZ at $7.7, after crossing above the $7.638 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of AWEVF at $1.5, after crossing above the $1.494 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of GHY at $12.43, after crossing above the $12.406 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of KBDC at $16.39, after crossing above the $16.289 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of ADT at $7.89, after crossing above the $7.854 Trigger Price

Suven Pharmaceuticals to acquire controlling stake in US-based company NJ Bio

New Delhi [India], December 7 (ANI): Listed pharma company, Suven Pharmaceuticals has announced the acquisition of a controlling stake in US-based NJ Bio Inc. The company informed stock exchanges that the controlling stake came with an investment of USD 64.4 million. Show Full Article The transaction is expected to close before the end of December […]
Suven Pharmaceuticals, an Indian company, has agreed to acquire a controlling 51% stake in the US-based NJ Bio for $40.25 million, with the deal expected to close by the end of March 2024. NJ Bio, established in 2012 in New Jersey, specializes in developing and manufacturing oligonucleotides, which are used in advanced therapies like antisense and RNA interference. This acquisition will allow Suven to expand its capabilities in the oligonucleotide sector, enhancing its global presence and supporting its growth strategy in the pharmaceutical industry.

Read the Full ThePrint Article at:
https://theprint.in/economy/suven-pharmaceuticals-to-acquire-controlling-stake-in-us-based-company-nj-bio/2392498/